That said, many such MRD monitoring tests rely upon serial increasing values to identify advancing leukemia (e.g. immunoglobulin receptor sequencing or BCR-ABL levels), thus diminishing the emphasis of certainty regarding the impact of a single value that is ‘positive’ at a single timepoint post-HCT. This evidence concerns the gene ABL1 and leukemia.